Trials / Completed
CompletedNCT02891226
A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 191 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirikizumab | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-12-14
- Primary completion
- 2018-12-11
- Completion
- 2021-02-05
- First posted
- 2016-09-07
- Last updated
- 2022-08-30
- Results posted
- 2022-02-28
Locations
108 sites across 14 countries: United States, Australia, Belgium, Canada, Czechia, Hungary, Japan, Netherlands, Poland, Romania, Russia, Switzerland, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT02891226. Inclusion in this directory is not an endorsement.